<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(3)</volume><submitter>Duivenvoorden WCM</submitter><pubmed_abstract>Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ&lt;sup>-/-&lt;/sup>:low-density lipoprotein receptor (LDLR)&lt;sup>-/-&lt;/sup> mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR&lt;sup>-/-&lt;/sup> mice, but not following FSH delivery. Smaller plaque burden in LDLR&lt;sup>-/-&lt;/sup> mice receiving gonadotropin-releasing hormone antagonists vs agonists were nullified in FSHβ&lt;sup>-/-&lt;/sup>:LDLR&lt;sup>-/-&lt;/sup> mice. Atherosclerotic and necrotic plaque size and macrophage infiltration correlated with serum FSH/T. In patients with prostate cancer, FSH/T following androgen-deprivation therapy initiation predicted cardiovascular events. FSH facilitates cardiovascular disease when T is low or eliminated.</pubmed_abstract><journal>JACC. Basic to translational science</journal><pagination>364-379</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10978407</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels.</pubmed_title><pmcid>PMC10978407</pmcid><pubmed_authors>Khajehei M</pubmed_authors><pubmed_authors>Pinthus JH</pubmed_authors><pubmed_authors>Subramony Gayathri V</pubmed_authors><pubmed_authors>Margel D</pubmed_authors><pubmed_authors>Duivenvoorden WCM</pubmed_authors><pubmed_authors>Duceppe E</pubmed_authors><pubmed_authors>Yousef S</pubmed_authors><pubmed_authors>Naeim M</pubmed_authors><pubmed_authors>Hopmans S</pubmed_authors><pubmed_authors>Devereaux PJ</pubmed_authors><pubmed_authors>Ber Y</pubmed_authors><pubmed_authors>Popovic S</pubmed_authors><pubmed_authors>Heels-Ansdell D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels.</name><description>Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ&lt;sup>-/-&lt;/sup>:low-density lipoprotein receptor (LDLR)&lt;sup>-/-&lt;/sup> mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR&lt;sup>-/-&lt;/sup> mice, but not following FSH delivery. Smaller plaque burden in LDLR&lt;sup>-/-&lt;/sup> mice receiving gonadotropin-releasing hormone antagonists vs agonists were nullified in FSHβ&lt;sup>-/-&lt;/sup>:LDLR&lt;sup>-/-&lt;/sup> mice. Atherosclerotic and necrotic plaque size and macrophage infiltration correlated with serum FSH/T. In patients with prostate cancer, FSH/T following androgen-deprivation therapy initiation predicted cardiovascular events. FSH facilitates cardiovascular disease when T is low or eliminated.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-25T18:56:46.774Z</modification><creation>2025-04-06T07:46:07.047Z</creation></dates><accession>S-EPMC10978407</accession><cross_references><pubmed>38559622</pubmed><doi>10.1016/j.jacbts.2023.10.010</doi></cross_references></HashMap>